Erratum: Mid-season real-time estimates of seasonal influenza vaccine effectiveness in persons 65 years and older in register-based surveillance, Stockholm County, Sweden, and Finland, January 2017 (Eurosurveillance, (2017) 28,8, 10.2807/1560-7917.ES.2017.22.8.30469);Mid-season real-time estimates of seasonal influenza vaccine effectiveness in persons 65 years and older in register-based surveillance, stockholm county, Sweden, and Finland, January 2017

Eurosurveillance

Volumn 22, Issue 8, 2017, Pages

  Hergens, Maria Pia ^a   Baum, Ulrike ^b   Brytting, Mia ^c   Ikonen, Niina ^b   Haveri, Anu ^b   Wiman, Åsa ^c   Nohynek, Hanna ^b   Örtqvist, Åke ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE; VIRUS ANTIGEN;

AGED; AMINO ACID SUBSTITUTION; ARTICLE; COHORT ANALYSIS; DISEASE CONTROL; DISEASE SURVEILLANCE; DNA SEQUENCE; DRUG EFFICACY; EPIDEMIC; FEMALE; FINLAND; HUMAN; INFLUENZA A VIRUS (H3N2); INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; PHYLOGENY; SEASONAL INFLUENZA; SENSITIVITY ANALYSIS; SWEDEN; VACCINE IMMUNOGENICITY; VERY ELDERLY; AGE DISTRIBUTION; GENETICS; HEALTH SURVEY; IMMUNOLOGY; INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; PROPORTIONAL HAZARDS MODEL; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY TRACT INFECTIONS; SEASON; SEX RATIO; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VACCINATION; VIROLOGY;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; FEMALE; FINLAND; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; PHYLOGENY; POPULATION SURVEILLANCE; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; RESPIRATORY TRACT INFECTIONS; SEASONS; SEX DISTRIBUTION; SWEDEN; TREATMENT OUTCOME; VACCINATION;

EID: 85014681551     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES.2017.22.9.30475     Document Type: Erratum

References (20)

1. Leval A, Hergens MP, Persson K, Örtqvist Å. Real-time realworld analysis of seasonal influenza vaccine effectiveness: method development and assessment of a population-based cohort in Stockholm County, Sweden, seasons 2011/12 to 2014/15. Euro Surveill. 2016;21(43): 30381. DOI: 10.2807/1560- 7917.ES.2016.21.43.30381 PMID: 27813473
2. Nohynek H, Baum U, Syrjänen R, Ikonen N, Sundman J, Jokinen J. Effectiveness of the live attenuated and the inactivated influenza vaccine in two-year-olds - a nationwide cohort study Finland, influenza season 2015/16. Euro Surveill. 2016;21(38):30346. DOI: 10.2807/1560-7917.ES.2016.21.38.30346 PMID: 27684447
3. Carlsson AC, Wändell P, Ösby U, Zarrinkoub R, Wettermark B, Ljunggren G. High prevalence of diagnosis of diabetes, depression, anxiety, hypertension, asthma and COPD in the total population of Stockholm, Sweden - a challenge for public health.BMC Public Health. 2013;13(1):670. DOI: 10.1186/1471-2458-13-670 PMID: 23866784
4. Rolfhamre P, Jansson A, Arneborn M, Ekdahl K. SmiNet-2: Description of an internet-based surveillance system for communicable diseases in Sweden. Euro Surveill. 2006;11(5):103-7. PMID: 16757847
5. Szegö J. Bebyggelsens mosaic. [The mosaic of the settlement]. Regionplanekontoret, Stockholm report no 7:2009. Stockholm: Regionplanekontoret; 2009. Swedish. Available from: http://www.rufs.se/publikationer/20092/20097-bebyggelsensmosaik/ Error! Hyperlink reference not valid.
6. Ministry of Social Affairs and Health. Communicable Disease Act No. 583/1986. Helsinki: Ministry of Social Affairs and Health; 25 July 1986. Available from: http://www.finlex.fi/fi/ laki/kaannokset/1986/en19860583.pdf
7. European Centre for Disease Prevention and Control (ECDC). Influenza virus characterisation, summary Europe, September 2016. Stockholm: ECDC; 2016. Available from: http://ecdc. europa.eu/en/publications/Publications/influenza-viruscharacterisation- september-2016.pdf
8. Kissling E, Nunes B, Robertson C, Valenciano M, Reuss A, Larrauri A, et al. I-MOVE multicentre case-control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination? Euro Surveill. 2016;21(16):30201. DOI: 10.2807/1560-7917.ES.2016.21.16.30201 PMID: 27124420
9. Leung VK, Cowling BJ, Feng S, Sullivan SG. Concordance of interim and final estimates of influenza vaccine effectiveness: a systematic review. Euro Surveill. 2016;21(16):30202. DOI: 10.2807/1560-7917.ES.2016.21.16.30202 PMID: 27124573
10. Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter AL, Dickinson JA, et al. A Perfect Storm: Impact of Genomic Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014-2015 Season. Clin Infect Dis. 2016;63(1):21-32. DOI: 10.1093/cid/ciw176 PMID: 27025838
11. Skowronski DM, Janjua NZ, De Serres G, Sabaiduc S, Eshaghi A, Dickinson JA, et al. Low 2012-13 influenza vaccine effectiveness associated with mutation in the eggadapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS One. 2014;9(3):e92153. DOI: 10.1371/journal.pone.0092153 PMID: 24667168
12. Ferdinands JM, Fry AM, Reynolds S, Petrie J, Flannery B, Jackson ML, et al. Intraseason waning of influenza vaccine protection: Evidence from the US Influenza Vaccine Effectiveness Network, 2011-12 through 2014-15. Clin Infect Dis. 2016;ciw816. DOI: 10.1093/cid/ciw816 PMID: 28039340
13. Belongia EA, Sundaram ME, McClure DL, Meece JK, Ferdinands J, VanWormer JJ. Waning vaccine protection against influenza A (H3N2) illness in children and older adults during a single season. Vaccine. 2015;33(1):246-51. DOI: 10.1016/j.vaccine.2014.06.052 PMID: 24962752
14. Long J, Bushnell RV, Tobin JK, Pan K, Deem MW, Nara PL, et al. Evolution of H3N2 influenza virus in a guinea pig model. PLoS One. 2011;6(7):e20130. DOI: 10.1371/journal.pone.0020130 PMID: 21799726
15. Ekiert DC, Kashyap AK, Steel J, Rubrum A, Bhabha G, Khayat R, et al. Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature. 2012;489(7417):526-32. DOI: 10.1038/nature11414 PMID: 22982990
16. 2), Canada, January 2017. Euro Surveill. 2017;22(6):30460. DOI: 10.2807/1560-7917. ES.2017.22.6.30460 PMID: 28205503
17. Belongia EA, Simpson MD, King JP, Sundaram ME, Kelley NS, Osterholm MT, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of testnegative design studies. Lancet Infect Dis. 2016;16(8):942-51. DOI: 10.1016/S1473-3099(16)00129-8 PMID: 27061888
18. DiazGranados CA, Robertson CA, Talbot HK, Landolfi V, Dunning AJ, Greenberg DP. Prevention of serious events in adults 65 years of age or older: A comparison between high-dose and standard-dose inactivated influenza vaccines. Vaccine. 2015;33(38):4988-93. DOI: 10.1016/j.vaccine.2015.07.006 PMID: 26212007
19. DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, et al. Efficacy of high-dose versus standarddose influenza vaccine in older adults. N Engl J Med. 2014;371(7):635-45. DOI: 10.1056/NEJMoa1315727 PMID: 25119609
20. 59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine. 2014;32(39):5027-34. DOI: 10.1016/j.vaccine.2014.07.013 PMID: 25045825